{"success":true,"data":{"pressRelease":{"id":"164173","rtpr_id":"nACSG721ta-20261008","ticker":"SBFM","exchange":"NASDAQ","all_tickers":["SBFM"],"title":"Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering","author":"ACCESSWIRE","published_at":"2026-10-08T12:00:00.780Z","article_body":"FORT LAUDERDALE, FL / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \"Company\"), a\npharmaceutical company specializing in generic and specialty prescription\nmedications, including drugs in the areas of oncology and antivirals, today\nannounced the pricing of a public offering made on a reasonable best efforts\nbasis with gross proceeds to the Company expected to be approximately $6.0\nmillion, before deducting placement agent fees and other offering expenses\npayable by the Company.\n\nThe offering consists of 10,909,083 Common Units (or Pre-Funded Units), each\nconsisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant\nand (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock\nper warrant at an initial exercise price of $0.66. The public offering price\nper Common Unit is $0.55 (or $0.54999 per Pre-Funded Unit, which is equal to\nthe public offering price per Common Unit minus an exercise price of $0.00001\nper share under the Pre-Funded Warrants). The Pre-Funded Warrants will be\nimmediately exercisable and may be exercised at any time until exercised in\nfull. The Series D Warrants will be exercisable immediately and expire five\nyears after the initial issuance date. The exercise price and number of shares\nissuable under the Series D Warrants are subject to adjustment as described in\nmore detail in the final prospectus to be filed in connection with the\noffering.\n\nThe transaction is expected to close on or about October 9, 2026, subject to\nthe satisfaction of customary closing conditions. The Company expects to use\nthe net proceeds from the offering for general corporate purposes and working\ncapital.\n\nAegis Capital Corp. is acting as the exclusive placement agent for the\noffering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the\nCompany. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.\n\nA registration statement on Form S-1 (No. 333-299274) previously filed with\nthe U.S. Securities and Exchange Commission (the \"SEC\") on October 2, 2026 was\ndeclared effective by the SEC on October 7, 2026. The offering is being made\nonly by means of a prospectus. A final prospectus describing the terms of the\noffering will be filed with the SEC and will be available on the SEC's website\nlocated at www.sec.gov. Electronic copies of the final prospectus may be\nobtained, when available, by contacting Aegis Capital Corp., Attention:\nSyndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY\n10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212)\n813-1010. Before investing in this offering, interested parties should read\nthe prospectus in its entirety, which provides more information about the\nCompany and such offering.\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy, nor shall there be any sale of these securities in any state\nor jurisdiction in which such an offer, solicitation or sale would be unlawful\nprior to registration or qualification under the securities laws of any such\nstate or jurisdiction.\n\nAbout Sunshine Biopharma Inc.\n\nSunshine Biopharma currently has 61 generic prescription drugs on the market\nin Canada and\napproximately 11 additional drugs expected to be launched in the remainder of\n2026. In addition, Sunshine Biopharma is conducting a proprietary drug\ndevelopment program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid\nNanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a\nsmall-molecule for treatment of SARS Coronavirus infections. For more\ninformation, please visit: www.sunshinebiopharma.com.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nSection 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934, each as amended. Forward-looking statements include all\nstatements that do not relate solely to historical or current facts, including\nwithout limitation statements regarding the Company's product development and\nbusiness prospects, the closing of the offering, and the use of proceeds from\nthe offering, and can be identified by the use of words such as \"may,\" \"will,\"\n\"expect,\" \"project,\" \"estimate,\" \"anticipate,\" \"plan,\" \"believe,\" \"potential,\"\n\"should,\" \"continue\" or the negative versions of those words or other\ncomparable words. Forward-looking statements are not guarantees of future\nactions or performance. These forward-looking statements are based on\ninformation currently available to the Company and its current plans or\nexpectations and are subject to a number of risks and uncertainties that could\nsignificantly affect current plans, including the risk factors described in\nthe Company's documents filed with the Securities and Exchange Commission.\nActual results may differ significantly from those anticipated, believed,\nestimated, expected, intended, or planned as a result of these risks. Although\nthe Company believes that the expectations reflected in the forward-looking\nstatements are reasonable, the Company cannot guarantee future results,\nperformance, or achievements. Except as required by applicable law, including\nthe securities laws of the United States, the Company does not intend to\nupdate any of the forward-looking statements to conform these statements to\nactual results.\n\nFor more information, please contact:\n\nCamille Sebaaly, CFO\nDirect Line: 514‑814‑0464\ncamille.sebaaly@sunshinebiopharma.com\n\nSOURCE: Sunshine Biopharma Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/sunshine-biopharma-inc.-announces-pricing-of-6.0-million-public-offer-1234227)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSG721ta-20261008","title":"Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering","author":"ACCESSWIRE","ticker":"SBFM","created":"2026-10-08T12:00:00.780Z","tickers":["SBFM"],"exchange":"NASDAQ","article_body":"FORT LAUDERDALE, FL / ACCESS Newswire (https://www.accessnewswire.com/) /\nOctober 8, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the \"Company\"), a\npharmaceutical company specializing in generic and specialty prescription\nmedications, including drugs in the areas of oncology and antivirals, today\nannounced the pricing of a public offering made on a reasonable best efforts\nbasis with gross proceeds to the Company expected to be approximately $6.0\nmillion, before deducting placement agent fees and other offering expenses\npayable by the Company.\n\nThe offering consists of 10,909,083 Common Units (or Pre-Funded Units), each\nconsisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant\nand (ii) two (2) Series D Warrants to purchase one (1) share of Common Stock\nper warrant at an initial exercise price of $0.66. The public offering price\nper Common Unit is $0.55 (or $0.54999 per Pre-Funded Unit, which is equal to\nthe public offering price per Common Unit minus an exercise price of $0.00001\nper share under the Pre-Funded Warrants). The Pre-Funded Warrants will be\nimmediately exercisable and may be exercised at any time until exercised in\nfull. The Series D Warrants will be exercisable immediately and expire five\nyears after the initial issuance date. The exercise price and number of shares\nissuable under the Series D Warrants are subject to adjustment as described in\nmore detail in the final prospectus to be filed in connection with the\noffering.\n\nThe transaction is expected to close on or about October 9, 2026, subject to\nthe satisfaction of customary closing conditions. The Company expects to use\nthe net proceeds from the offering for general corporate purposes and working\ncapital.\n\nAegis Capital Corp. is acting as the exclusive placement agent for the\noffering. Sichenzia Ross Ference Carmel LLP is acting as counsel to the\nCompany. Kaufman & Canoles, P.C. is acting as counsel to Aegis Capital Corp.\n\nA registration statement on Form S-1 (No. 333-299274) previously filed with\nthe U.S. Securities and Exchange Commission (the \"SEC\") on October 2, 2026 was\ndeclared effective by the SEC on October 7, 2026. The offering is being made\nonly by means of a prospectus. A final prospectus describing the terms of the\noffering will be filed with the SEC and will be available on the SEC's website\nlocated at www.sec.gov. Electronic copies of the final prospectus may be\nobtained, when available, by contacting Aegis Capital Corp., Attention:\nSyndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY\n10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212)\n813-1010. Before investing in this offering, interested parties should read\nthe prospectus in its entirety, which provides more information about the\nCompany and such offering.\n\nThis press release shall not constitute an offer to sell or a solicitation of\nan offer to buy, nor shall there be any sale of these securities in any state\nor jurisdiction in which such an offer, solicitation or sale would be unlawful\nprior to registration or qualification under the securities laws of any such\nstate or jurisdiction.\n\nAbout Sunshine Biopharma Inc.\n\nSunshine Biopharma currently has 61 generic prescription drugs on the market\nin Canada and\napproximately 11 additional drugs expected to be launched in the remainder of\n2026. In addition, Sunshine Biopharma is conducting a proprietary drug\ndevelopment program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid\nNanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a\nsmall-molecule for treatment of SARS Coronavirus infections. For more\ninformation, please visit: www.sunshinebiopharma.com.\n\nForward-Looking Statements\n\nThis press release contains \"forward-looking statements\" within the meaning of\nSection 27A of the Securities Act of 1933 and Section 21E of the Securities\nExchange Act of 1934, each as amended. Forward-looking statements include all\nstatements that do not relate solely to historical or current facts, including\nwithout limitation statements regarding the Company's product development and\nbusiness prospects, the closing of the offering, and the use of proceeds from\nthe offering, and can be identified by the use of words such as \"may,\" \"will,\"\n\"expect,\" \"project,\" \"estimate,\" \"anticipate,\" \"plan,\" \"believe,\" \"potential,\"\n\"should,\" \"continue\" or the negative versions of those words or other\ncomparable words. Forward-looking statements are not guarantees of future\nactions or performance. These forward-looking statements are based on\ninformation currently available to the Company and its current plans or\nexpectations and are subject to a number of risks and uncertainties that could\nsignificantly affect current plans, including the risk factors described in\nthe Company's documents filed with the Securities and Exchange Commission.\nActual results may differ significantly from those anticipated, believed,\nestimated, expected, intended, or planned as a result of these risks. Although\nthe Company believes that the expectations reflected in the forward-looking\nstatements are reasonable, the Company cannot guarantee future results,\nperformance, or achievements. Except as required by applicable law, including\nthe securities laws of the United States, the Company does not intend to\nupdate any of the forward-looking statements to conform these statements to\nactual results.\n\nFor more information, please contact:\n\nCamille Sebaaly, CFO\nDirect Line: 514‑814‑0464\ncamille.sebaaly@sunshinebiopharma.com\n\nSOURCE: Sunshine Biopharma Inc.\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/sunshine-biopharma-inc.-announces-pricing-of-6.0-million-public-offer-1234227)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-10-08T12:00:00.971128453Z","server_sent_at_ms":1791460800971},"received_at":"2026-10-08T12:00:01.020Z","source_url":"https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/sunshine-biopharma-inc.-announces-pricing-of-6.0-million-public-offer-1234227"},"analysis":{"id":"152612","press_release_id":"164173","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["Heavy warrant coverage: two Series D Warrants per unit adds substantial potential dilution beyond the 10.9M headline shares","Use of proceeds is 'general corporate purposes and working capital' — no specific project funded","Micro-cap penny-stock-priced raise ($0.55/unit) via best-efforts offering"],"eventType":"offering","narrative":"Sunshine Biopharma priced a best-efforts public offering of 10,909,083 common units at $0.55 per unit for approximately $6.0 million in gross proceeds.\n\nEach unit includes one share (or pre-funded warrant) plus two Series D Warrants exercisable at $0.66 and expiring in five years, meaning potential dilution roughly triples the headline share count.\n\nProceeds are earmarked for general corporate purposes and working capital; the deal is expected to close on or about October 9, 2026, with Aegis Capital as exclusive placement agent.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"$6M dilutive raise with 2x warrant coverage at $0.55 — watch SBFM pressure on warrant overhang."},"keyFigures":{"dealValueUsd":6000000,"offeringPrice":0.55,"sharesOffered":10909083,"customDimensions":{"warrant_term":"five years","expected_close":"October 9, 2026","warrants_per_unit":2,"prefunded_unit_price":"$0.54999","warrant_exercise_price":0.66}},"namedEntities":{"people":[{"name":"Camille Sebaaly","role":"CFO"}],"products":["K1.1 mRNA","PLpro protease inhibitor","Series D Warrants","Pre-Funded Warrants"],"companies":[{"name":"Sunshine Biopharma Inc.","ticker":"SBFM","relationship":"issuer"},{"name":"Aegis Capital Corp.","relationship":"placement agent"},{"name":"Sichenzia Ross Ference Carmel LLP","relationship":"company counsel"},{"name":"Kaufman & Canoles, P.C.","relationship":"placement agent counsel"}],"dollarAmounts":[{"amount":"$6.0 million","context":"gross proceeds of public offering"},{"amount":"$0.55","context":"public offering price per Common Unit"},{"amount":"$0.54999","context":"price per Pre-Funded Unit"},{"amount":"$0.66","context":"Series D Warrant initial exercise price"},{"amount":"$0.00001","context":"Pre-Funded Warrant exercise price"}]},"materialImpact":{"score":4,"reasoning":"Micro-cap biopharma raised ~$6.0M at $0.55/unit with heavy warrant coverage (2 Series D warrants per unit at $0.66 exercise), a highly dilutive structure. Prior close not stated, so no below-market discount flag per rules."},"tickerRelevance":{"others":[],"primary":"SBFM"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"dilutive micro-cap offering","retailFavoriteBoost":"low-priced biotech with some retail attention"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":4,"narrative":"Sunshine Biopharma priced a best-efforts public offering of 10,909,083 common units at $0.55 per unit for approximately $6.0 million in gross proceeds.\n\nEach unit includes one share (or pre-funded warrant) plus two Series D Warrants exercisable at $0.66 and expiring in five years, meaning potential dilution roughly triples the headline share count.\n\nProceeds are earmarked for general corporate purposes and working capital; the deal is expected to close on or about October 9, 2026, with Aegis Capital as exclusive placement agent.","key_figures":{"dealValueUsd":6000000,"offeringPrice":0.55,"sharesOffered":10909083,"customDimensions":{"warrant_term":"five years","expected_close":"October 9, 2026","warrants_per_unit":2,"prefunded_unit_price":"$0.54999","warrant_exercise_price":0.66}},"named_entities":{"people":[{"name":"Camille Sebaaly","role":"CFO"}],"products":["K1.1 mRNA","PLpro protease inhibitor","Series D Warrants","Pre-Funded Warrants"],"companies":[{"name":"Sunshine Biopharma Inc.","ticker":"SBFM","relationship":"issuer"},{"name":"Aegis Capital Corp.","relationship":"placement agent"},{"name":"Sichenzia Ross Ference Carmel LLP","relationship":"company counsel"},{"name":"Kaufman & Canoles, P.C.","relationship":"placement agent counsel"}],"dollarAmounts":[{"amount":"$6.0 million","context":"gross proceeds of public offering"},{"amount":"$0.55","context":"public offering price per Common Unit"},{"amount":"$0.54999","context":"price per Pre-Funded Unit"},{"amount":"$0.66","context":"Series D Warrant initial exercise price"},{"amount":"$0.00001","context":"Pre-Funded Warrant exercise price"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T12:00:17.023Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","eventGravity":"dilutive micro-cap offering","retailFavoriteBoost":"low-priced biotech with some retail attention"}},"durationMs":8826,"modelName":"glm-5.3-flashx"}}